FDA's new Guidance Documents for 2012
The U.S. Food and Drug Administration FDA has issued its yearly list of planned draft and final guidance documents for 2012. There are about 50 such guidance documents planned.
This is an overview about some important ones:
Biopharmaceutics and Biosimilarity:
- Scientific Considerations in Demonstrating Biosimilarity To a Reference Product
- Quality Considerations in Demonstrating Biosimilarity To a Reference Protein Product
Combination Products:
- Development of Drugs in Combination
cGMPs and Compliance:
- Control of Highly Potent Compounds
- Importation of Active Pharmaceutical Ingredients (API) for Use in Human Drugs
Labeling, Packaging and Supply Chain:
- Securing the Drug Supply Chain-Standards for Tracking and Tracing Prescription Drug Packages
- Pediatric Information: Incorporating into Human Prescription Drug and Biological Products Labeling
Source: FDA Guidance Agenda
Compiled by
Wolfgang Schmitt
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)
Related GMP News
26.06.202410 points on how the FDA's CDER monitors the Quality of Medicinal Products
08.05.2024EMA Plans for the next three Years
30.04.2024Lean GMP: is "right-sizing" GMP and Compliance possible?
24.04.2024Unexpected Deviations: the Role of the QP
10.04.2024FDA's current Thinking on KPIs and Quality Metrics
21.02.2024What is the African Medicines Agency?